IRWD · Company research
Ironwood Pharmaceuticals, Inc. - (IRWD): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis - Stock Titan | Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Ironwood Pharmaceuticals (IRWD) Slips 1.29% to $3.82 as Shares Drift Toward Support - Factor Rotation - https://www.dars.gov.et/ | Ironwood Pharmaceuticals (IRWD) Slips 1.29% to $3.82 as Shares Drift Toward Support - Factor Rotation https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Oct 10, 2026 | neutral | 0 | 0.6 |
| Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? | Ironwood Pharmaceuticals (IRWD) is experiencing strong prescription demand for its primary product Linzess, with U.S. net profit share surging 72.6% year-over-year in the first half of 2026. The company raised its full-year 2026 revenue guidance to $460-$485 million, citing continued momentum from Linzess sales, recent FDA label expansion for pediatric patients, and favorable pricing dynamics. IRWD stock is trading at a valuation discount to the industry and carries a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.25 | 1 |
| Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? | Ironwood Pharmaceuticals (IRWD) is experiencing strong prescription demand for its primary product Linzess, with U.S. net profit share surging 72.6% year-over-year in the first half of 2026. The company raised its full-year 2026 revenue guidance to $460-$485 million, citing continued momentum from Linzess sales, recent FDA label expansion for pediatric patients, and favorable pricing dynamics. IRWD stock is trading at a valuation discount to the industry and carries a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.25 | 1 |
| Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy - Seeking Alpha | Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy Seeking Alpha | View source ↗ | Seeking Alpha | Oct 7, 2026 | neutral | 0 | 0.6 |
| Ironwood Pharmaceuticals (Nasdaq:IRWD) - Stock Analysis - Simply Wall Street | Ironwood Pharmaceuticals (Nasdaq:IRWD) - Stock Analysis Simply Wall Street | View source ↗ | Simply Wall Street | Oct 7, 2026 | neutral | 0 | 0.6 |
| PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Zacks Investment Research | PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? Zacks Investment Research | View source ↗ | Zacks Investment Research | Sep 30, 2026 | neutral | 0 | 0.6 |
| 83,306 shares to cover taxes: Ironwood Pharmaceuticals (IRWD) ex-officer proposes a sale - Stock Titan | 83,306 shares to cover taxes: Ironwood Pharmaceuticals (IRWD) ex-officer proposes a sale Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| Ironwood Pharmaceuticals (NASDAQ:IRWD) Highlights Minervini Trend Template and High Growth Momentum - ChartMill | Ironwood Pharmaceuticals (NASDAQ:IRWD) Highlights Minervini Trend Template and High Growth Momentum ChartMill | View source ↗ | ChartMill | Aug 26, 2026 | neutral | 0 | 0.6 |
| Ironwood Pharmaceuticals (IRWD) Stock Faces A Sentiment Check After Raised Guidance - Simply Wall Street | Ironwood Pharmaceuticals (IRWD) Stock Faces A Sentiment Check After Raised Guidance Simply Wall Street | View source ↗ | Simply Wall Street | Aug 7, 2026 | neutral | 0 | 0.6 |
| FDA approves Ironwood's LINZESS for functional constipation in children 2+ - Stock Titan | FDA approves Ironwood's LINZESS for functional constipation in children 2+ Stock Titan | View source ↗ | Stock Titan | Aug 6, 2026 | neutral | 0 | 0.6 |
| Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed? - Yahoo Finance | Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 6, 2026 | neutral | 0 | 0.6 |
| $IRWD stock is up 8% today. Here's what we see in our data. - Quiver Quantitative | $IRWD stock is up 8% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 31, 2026 | neutral | 0 | 0.6 |
| Ironwood Pharmaceuticals: One Trial Stands Between Bargain And Bust (NASDAQ:IRWD) - Seeking Alpha | Ironwood Pharmaceuticals: One Trial Stands Between Bargain And Bust (NASDAQ:IRWD) Seeking Alpha | View source ↗ | Seeking Alpha | Jul 30, 2026 | neutral | 0 | 0.6 |
| IRWD Forecast — Price Target — Prediction for 2027 - TradingView | IRWD Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| Ironwood Pharmaceuticals: A Contrarian Buy Opportunity (NASDAQ:IRWD) - Seeking Alpha | Ironwood Pharmaceuticals: A Contrarian Buy Opportunity (NASDAQ:IRWD) Seeking Alpha | View source ↗ | Seeking Alpha | May 21, 2026 | neutral | 0 | 0.6 |
| IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock? - Yahoo Finance | IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Mar 30, 2026 | neutral | 0 | 0.6 |
| $IRWD stock is down 15% today. Here's what we see in our data. - Quiver Quantitative | $IRWD stock is down 15% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Feb 20, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.